Investors who own more than 5% of a class must file a Schedule 13D or 13G. Every filing for 92673K108 since 12/18/2024, newest first.
| Filer | % of Class | Filed | |
|---|---|---|---|
|
Beryl Capital Management LLC
13G/A
Amendment 1
|
0% |
11/14/2025
Event 9/30/2025
|
|
| Beryl Capital Management LLC | 0% | ||
| Beryl Capital Management LP | 0% | ||
| Beryl Capital Partners II LP | 0% | ||
| David A. Witkin | 0% | ||
|
Glazer Capital, LLC
13G/A
Amendment 1
|
6.5% |
8/14/2025
Event 6/30/2025
|
|
| Glazer Capital, LLC | 6.5% | ||
| Paul J. Glazer | 6.5% | ||
|
Biotechnology Value Fund L P
13G/A
Amendment 2
|
0% |
8/14/2025
Event 6/30/2025
|
|
| Biotechnology Value Fund L P | 0% | ||
| BVF I GP LLC | 0% | ||
| Biotechnology Value Fund II LP | 0% | ||
| BVF II GP LLC | 0% | ||
| Biotechnology Value Trading Fund OS LP | 0% | ||
| BVF Partners OS Ltd. | 0% | ||
| BVF GP Holdings LLC | 0% | ||
| BVF Partners L P/IL | 0% | ||
| BVF Inc/IL | 0% | ||
| Lampert Mark N | 0% | ||
|
Atlas Venture Fund XII, L.P.
13D/A
Amendment 1
|
0% |
8/7/2025
Event 8/5/2025
|
|
| Atlas Venture Fund XII, L.P. | 0% | ||
| Atlas Venture Associates XII, L.P. | 0% | ||
| Atlas Venture Associates XII, LLC | 0% | ||
| Atlas Venture Opportunity Fund I, L.P. | 0% | ||
| Atlas Venture Associates Opportunity I, L.P. | 0% | ||
| Atlas Venture Associates Opportunity I, LLC | 0% | ||
|
Vida Ventures GP III, L.L.C.
13D/A
Amendment 3
|
3.5% |
6/12/2025
Event 6/10/2025
|
|
| Vida Ventures III, L.P. | 3.5% | ||
| Vida Ventures III-A, L.P. | 0% | ||
| Vida Ventures GP III, L.L.C. | 3.5% | ||
|
Vida Ventures GP III, L.L.C.
13D/A
Amendment 2
|
6.1% |
6/9/2025
Event 6/5/2025
|
|
| Vida Ventures III, L.P. | 6.1% | ||
| Vida Ventures III-A, L.P. | 0% | ||
| Vida Ventures GP III, L.L.C. | 6.1% | ||
|
Glazer Capital, LLC
13G
|
5.4% |
6/4/2025
Event 5/28/2025
|
|
| Glazer Capital, LLC | 5.4% | ||
| Paul J. Glazer | 5.4% | ||
|
Beryl Capital Management LLC
13G
|
9.9% |
5/30/2025
Event 5/22/2025
|
|
| Beryl Capital Management LLC | 9.9% | ||
| Beryl Capital Management LP | 9.9% | ||
| Beryl Capital Partners II LP | 8.0% | ||
| David A. Witkin | 9.9% | ||
|
Northpond Ventures, LP
13D/A
Amendment 2
|
0% |
5/27/2025
Event 5/22/2025
|
|
| Northpond Ventures, LP | 0% | ||
| Northpond Ventures GP, LLC | 0% | ||
| Northpond Ventures II, LP | 0% | ||
| Northpond Ventures II GP, LLC | 0% | ||
| Michael P. Rubin | 0% | ||
|
Biotechnology Value Fund L P
13G/A
Amendment 1
|
10.0% |
5/15/2025
Event 3/31/2025
|
|
| Biotechnology Value Fund L P | 5.4% | ||
| BVF I GP LLC | 5.4% | ||
| Biotechnology Value Fund II LP | 4.1% | ||
| BVF II GP LLC | 4.1% | ||
| Biotechnology Value Trading Fund OS LP | 0.5% | ||
| BVF Partners OS Ltd. | 0.5% | ||
| BVF GP Holdings LLC | 9.4% | ||
| BVF Partners L P/IL | 10.0% | ||
| BVF Inc/IL | 10.0% | ||
| Lampert Mark N | 10.0% | ||
|
Invus Global Management, LLC
13G/A
Amendment 1
|
4.9% |
2/12/2025
Event 12/31/2024
|
|
| Invus Public Equities, L.P. | 4.5% | ||
| Invus Public Equities Advisors, LLC | 4.5% | ||
| Invus Global Management, LLC | 4.5% | ||
| Siren, L.L.C. | 4.5% | ||
| Avicenna Life Sci Master Fund LP | 0.4% | ||
| Avicenna Life Sci Master GP LLC | 0.4% | ||
| Ulys, L.L.C. | 0.4% | ||
| Raymond Debbane | 4.9% |
| Period | Filings | Shares, Excl. Options | Value, Excl. Options |
|---|---|---|---|
| 2025 Q3 | 2 | 26.9 k | $4.55 k |
| 2025 Q2 | 80 | 33.4 M | $266 M |
| 2025 Q1 | 51 | 25.0 M | $44.5 M |
| 2024 Q4 | 52 | 22.6 M | $38.4 M |
| 2024 Q3 | 54 | 27.7 M | $94.5 M |
| 2024 Q2 | 61 | 26.2 M | $105 M |
| 2024 Q1 | 58 | 26.6 M | $90.7 M |
| 2023 Q4 | 50 | 25.1 M | $84.9 M |
| 2023 Q3 | 46 | 25.5 M | $138 M |
| 2023 Q2 | 48 | 25.8 M | $242 M |
| 2023 Q1 | 42 | 25.1 M | $246 M |
| 2022 Q4 | 39 | 25.0 M | $313 M |
| 2022 Q3 | 34 | 24.6 M | $223 M |
| 2022 Q2 | 36 | 17.3 M | $44.7 M |
| 2022 Q1 | 48 | 17.9 M | $125 M |